India · Delayed Price · Currency is INR Zydus Lifesciences Earnings Call Transcripts
Fiscal Year 2026
-
Q3 FY26 saw 30% revenue and 31% EBITDA growth, driven by strong performance across all segments and strategic acquisitions. Guidance remains robust for double-digit growth in India and international markets, with continued margin strength and innovation focus.
-
Q1 FY 2026 saw 6% revenue growth and 3% net profit growth year-on-year, with strong U.S., India, and international performance. Strategic acquisitions in medtech and biologics, robust innovation pipeline, and high cash reserves position the company for sustained growth.
Fiscal Year 2025
-
FY 2025 saw record revenue and profitability, with double-digit growth across key segments. Guidance for FY 2026 includes single-digit U.S. growth, double-digit India and emerging market growth, and EBITDA margin above 26%.
-
Strong double-digit revenue and profit growth was driven by robust U.S., India, and international businesses, with significant new product launches and innovation. The company improved margins, maintained a strong net cash position, and expects continued growth in FY25 and FY26.
-
Double-digit revenue and profit growth were driven by strong performance across India, US, and international markets, with robust new product launches and a strengthened innovation pipeline. Margin expansion and a solid net cash position support a positive outlook for FY25.
-
Q1 FY25 saw record revenues and margins, with all segments delivering strong growth. Guidance for high teens revenue growth and margin expansion is maintained, while US and international businesses are set for continued double-digit growth.